Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results

Rhythm Pharmaceuticals (RYTM) Tops Q3 EPS by 3c

November 1, 2019 8:36 AM EDT

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q3 EPS of ($1.04), $0.03 better than the analyst estimate of ($1.07).

Announced Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency ObesitiesAdded Four New MC4R Pathway Obesity Indications to Phase 2 Basket Study and Enrolling Patients --Announced Genetic Sequencing Data Supporting Ultra-Rarity of POMC and LEPR Deficiency Obesities and Suggesting U.S. Prevalence for Four New Basket Indications of > 60,000Successfully Completed $172.5 Million Public... More